Clinical Trials

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this trial is to find out if the addition of pembrolizumab to usual chemotherapy is better or worse than usual chemotherapy alone for non-small cell lung cancer.

Ottosen, Rebecca

ottosen.rebecca@marshfieldresearch.org

(715) 393-1471

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI  54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI  54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI  54494

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Ladysmith

906 College Ave W

Ladysmith, WI  54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Huotari, Cressa L

huotari.cressa@marshfieldresearch.org

Diagnostic & Treatment Center

3401 CRANBERRY BLVD

WESTON, WI  54476

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI  54401

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This phase II/III trial compares the effect of the combination of olaparib and temozolomide to the usual treatment (trabectedin and pazopanib) for uterine leiomyosarcoma that has spread to other places in the body (advanced) after initial chemotherapy has stopped working. Olaparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Temozolomide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. The combination of olaparib and temozolomide may work better than the usual treatment in shrinking or stabilizing advanced uterine leiomyosarcoma after initial chemotherapy has stopped working.

Huotari, Cressa L

huotari.cressa@marshfieldresearch.org

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Ottosen, Rebecca

ottosen.rebecca@marshfieldresearch.org

(715) 393-1471

Diagnostic & Treatment Center

3401 CRANBERRY BLVD

WESTON, WI  54476

Lakeview Medical Center

1700 West Stout Street

Rice Lake, WI  54868

Marshfield Clinic At James Beck Cancer Center

2251 NORTH SHORE DR

RHINELANDER, WI  54501

Marshfield Clinic Cancer Care At St Michaels

900 ILLINOIS AVE

STEVENS POINT, WI  54481

Marshfield Medical Center

611 Saint Joseph Ave

Marshfield, WI  54449

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI  54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI  54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI  54494

Mfld Clinic Cancer Care at Sacred Heart Hospital

900 W CLAIREMONT AVE

EAU CLAIRE, WI  54701

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Ladysmith

906 College Ave W

Ladysmith, WI  54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

Sacred Heart Hospital (Eau Claire)

900 W Clairemont Ave

Eau Claire, WI  54701

St. Mary's

2251 North Shore Drive

Rhinelander, WI  54501

St. Michaels Hospital

900 Illinois Ave

Stevens Point, WI  54481

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.

Humphrey, Logan J

humphrey.logan@marshfieldresearch.org

Diagnostic & Treatment Center

3401 CRANBERRY BLVD

WESTON, WI  54476

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI  54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI  54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI  54494

MMC - Eau Claire

2116 Craig Rd

Eau Claire, WI  54701

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Ladysmith

906 College Ave W

Ladysmith, WI  54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, in order to classify patients into post-consolidation treatment groups. On the second part of this study, patients will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase III trial compares the effect of adding levocarnitine to chemotherapy versus chemotherapy alone in protecting the liver in patients with leukemia and lymphoma. Standard of care chemotherapy treatment for leukemia and lymphoma includes a type of chemotherapy named asparaginase, given either as the drug pegaspargase, or a similar drug, calaspargase pegol. This type of chemotherapy can cause severe liver damage. Levocarnitine is a drug used to provide extra carnitine, a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is important to keep the liver healthy and may be able to prevent damage to the liver from chemotherapy and other drugs. Taking levocarnitine may reduce the rate of severe liver damage caused by asparaginase chemotherapy in patients with leukemia and lymphoma.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase III trial tests the addition of sodium thiosulfate to standard of care chemotherapy and radiation therapy in treating patients with low or average risk medulloblastoma (a type of cancer in the brain). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects are unintended problems that arise due to treatment such as learning difficulties, lower amounts of hormones, hearing problems, or other problems in performing daily activities. Patients with medulloblastoma often receive treatment with chemotherapy drugs including cisplatin. Cisplatin may cause hearing loss as a side effect. Previous studies with sodium thiosulfate have shown that it may help reduce or prevent hearing loss caused by cisplatin. This study looks at adding sodium thiosulfate to standard treatment for medulloblastoma (radiation therapy and chemotherapy, including cisplatin) to find out if it reduces hearing loss.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449